Feedback / Questions
remetinostat (SHP-141) - Medivir
Corporate presentation - October 2014
(TetraLogic Press Release)
-
Oct 23, 2014 -
"Phase 2 clinical trial with SHAPE (suberohydroxamic acid phenyl ester) in early-stage CTCL in 4Q14"
Anticipated new P2 trial
•
Hematological Malignancies • Oncology
http://tetralogicpharma.com/wp-content/wbuploads/wb_publications/TLOG_Corporate_Presentation_24_October_2014.pdf
Oct 23, 2014
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.